The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics

• Published in: Anti-cancer agents in medicinal chemistry Vol. 15; no. 7; p. 869
• Main Authors: Sun, Guang-Chun, Yang, Xu, Yu, Yan, Zhao, Dai-Wei
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2015
• Subjects: Angiogenesis Inhibitors - pharmacology; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasms - blood supply; Neoplasms - drug therapy; Neoplasms - metabolism; Protein-Tyrosine Kinases - antagonists & inhibitors; Protein-Tyrosine Kinases - metabolism; Receptor, Epidermal Growth Factor - antagonists & inhibitors
• ISSN: 1875-5992
• DOI: 10.2174/1871520615666150318101845

Anti-cancer targeting drugs appear to be a new and powerful "weapon" for cancer therapies. These targeting drugs are directed against specific molecules that are over-expressed or where certain unique factors are aberrantly expressed either in cancer cells or in diseased cell sites. Compared with traditional chemotherapeutic drugs, these targeting drugs have the advantages of high specificity, efficacy and less side effects. Target therapy is a breakthrough and revolutionary advance in the field of cancer therapy. Tumor angiogenesis plays a key role in tumor growth and metastasis and the mutation of tyrosine kinases is also strongly associated with cancer progression. Thus, in this review, we will discuss the advances in the development of targeting anti-cancer drugs by narrowing it down to small molecule tyrosine kinase inhibitors, monoclonal antibodies against epidermal growth factor receptors belonging to the ErbB family of receptor tyrosine kinases and angiogenic inhibitors. It will also address concerns for drug resistance and adverse events.